Article Text

Download PDFPDF
Neuroinflammation as a potential therapeutic target in dementia with Lewy bodies
  1. Hiroshige Fujishiro
  1. Correspondence to Dr Hiroshige Fujishiro, Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan; fujishiro17{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The more reliably identifiable prodromal phase of dementia with Lewy bodies than Alzheimer’s disease provides a critical opportunity for intervention

There is a great deal of evidence suggesting a fundamental role of central and peripheral inflammation in the pathogenesis of Alzheimer’s disease (AD).1 Neuropathological and neuroradiological studies have indicated that activated microglia and inflammation-related mediators is observed in the cerebral neocortex of patients with early AD before extensive tau-related neurofibrillary pathology develops. Numerous epidemiological studies have revealed that treatment with non-steroidal anti-inflammatory drugs decreases the risk for developing AD. However, several prospective clinical trials showed no benefit from anti-inflammatory drugs in patients with symptomatic AD. These results imply that therapies should be initiated during earlier stages of AD pathology. Although it has been established …

View Full Text


  • Contributors The author is the sole contributing writer of this manuscript.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Neuro-inflammation
    Eleanor King John Tiernan O’Brien Paul Donaghy Christopher Morris Nicola Barnett Kirsty Olsen Carmen Martin-Ruiz John-Paul Taylor Alan J Thomas